亚历山大与鲍德温公司 ALEX 深 沪
已收盘 08-01 16:00:00 美东时间
17.99
+0.010
+0.06%
华盛通- 最 高18.155
- 今 开18.06
- 成交量 56.04万股
- 最 低 17.90
- 昨 收 17.98
- 总市值 13.08亿
- 52周最高 19.29
- 市盈率 静 21.63
- 换手率 0.77%
- 52周最低 15.475
- 委 比 -64.37%
- 总股本 7271.15万
- 历史最高 26.2831
- 量 比 1.19
- 振 幅 1.42%
- 历史最低 2.0631
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多好未来单季营收5.75亿美元：同比增39% 彭壮壮及刘亚超刚减持百万
雷递网 乐天 7月31日 好未来(NYSE: TAL)今日发布截至2025年5月31日的财报。财报显示，截至2025年5月31日的季度，好未来营收为5.75亿美...
07-31 18:38
Alexander’s Declares Quarterly $4.50 Dividend on Common Shares
Alexander's, Inc. announced a regular quarterly dividend of $4.50 per share, payable on August 29, 2025, to stockholders of record on August 11, 2025. The company, a real estate investment trust with five properties in New York City, also included forward-looking statements that are subject to various risks and uncertainties, as detailed in its Annual Report on Form 10-K.
07-30 17:34
Earnings Scheduled For July 24, 2025
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is likely to repo...
07-24 16:32
A Preview Of Alexander & Baldwin's Earnings
Alexander & Baldwin (NYSE:ALEX) is set to give its latest quarterly earning...
07-24 05:01
Alexander & Baldwin Announces Third Quarter 2025 Dividend
HONOLULU, July 23, 2025 /PRNewswire/ -- Alexander & Baldwin, Inc. (NYSE: ALEX) ("A&B" or "Company") today announced that its Board of Directors approved a third quarter 2025 dividend of $0.2...
07-24 04:05
'European Commission Approves DARZALEX As The First Licensed Treatment For Patients With High-Risk Smouldering Multiple Myeloma" - Johnson & Johnson
https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma
07-23 20:42
好未来股权曝光：张邦鑫持股27.3%，有73%投票权 身价125亿
雷递网 雷建平 7月16日 好未来（股票代码：“TAL”）日前向美国SEC递交20-F文件，文件显示，截至2025年4月30日，好未来创始人、CEO张邦鑫持股...
07-16 18:42
Genmab Q2 Worldwide Net Trade Sales Of DARZALEX Totals $3.539B
Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN,
07-16 18:32
Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on the drugmaker’s guidance amid U.S. President Donald Trump’s ongoing threats ...
07-16 02:19
Earnings week ahead: JPM, BAC, GS, MS, C, JNJ, TSM, ABT, PEP, MMM, SLB, UAL, NFLX, and more
The upcoming week marks the beginning of earnings season, with a lineup of heavyweights across banking, healthcare, tech, and industrials. Big banks lead the charge with reports from JPMorgan Chase (N...
07-13 20:00
